Researchers propose new solutions to fill gaps in Medicare coverage Near-poor Americans-;people just above the federal poverty level but still well below the average U.S. income-;who rely on Medicare for health insurance face high medical bills and may forgo essential health care, according to new research led by health policy scientists at the University of Pittsburgh Graduate School of Public Health. This is due to a coverage cliff in Medicaid, which supplements Medicare for people with incomes below poverty but excludes individuals above the federal poverty threshold, including the near-poor.
In a report published today in the April issue of the journal
Moleculin Biotech Engages IQVIA To Manage Potential COVID-19 Clinical Trial
SOUTH SAN FRANCISCO (dpa-AFX) - Moleculin Biotech Inc. (MBRX) said that it has engaged IQVIA Biotech, a contract research organization, to manage the company s effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
WP1122 is a prodrug of 2-DG, a well-known antimetabolite with the ability to inhibit glycolysis and alter glycosylation, two processes critical to coronaviruses like SARS-CoV-2, the virus responsible for COVID-19.
The company noted that 2-DG has shown activity against SARS-CoV-2, other coronaviruses and other non-coronaviruses. But the company believes its therapeutic potential is limited by its inherent lack of drug-like properties.
(0)
NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a clinical study of TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR).
Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-10 in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents. This IND clearance is a key milestone for Tarus as we continue to advance our portfolio of adenosine receptor antagonists for cancer immunotherapy. We are pleased to be entering the clinic with our potentially best-in-class A2AR antagonist, said Sushant Kumar, Ph.D., Chief Executive Officer, Tarus Therapeutics. This is a very exciting moment for the
Prepare for COVID Medical Bills This Year
Amrita Jayakumar, NerdWallet
FacebookTwitterEmail
This article was first published on NerdWallet.com.
Testing and vaccination for the coronavirus are free thanks to laws passed last year. Treatment isn t, however, and may be about to get more expensive.
A new vaccine is in production, millions of doses are being administered daily and President Joe Biden says there will be enough vaccines for all U.S. adults by the end of May. That’s great news. But there s still a risk of getting COVID-19 and facing medical bills.
Here’s a primer to COVID-19 costs you could face, what insurers will pay for and how to deal with medical bills.
Biden s big infrastructure plan hits McConnell-GOP blockade
LISA MASCARO, AP Congressional Correspondent
April 5, 2021
FacebookTwitterEmail 6
1of6President Joe Biden talks with reporters on the Ellipse on the National Mall after spending the weekend at Camp David, Monday, April 5, 2021, in Washington.Evan Vucci/APShow MoreShow Less
2of6FILE - In this March 24, 2021, file photo Senate Minority Leader Mitch McConnell, R-Ky., listens as the Senate Rules Committee holds a hearing on the For the People Act, which would expand access to voting and other voting reforms, at the Capitol in Washington. Republicans in Congress are making the politically brazen bet that it’s more advantageous to oppose President Joe Biden’s ambitious rebuild America agenda than to lend support for the costly $2.3 trillion undertaking for roads, bridges and other infrastructure investments.J. Scott Applewhite/APShow MoreShow Less